


## Pazopanib-<sup>13</sup>C,<sub>3</sub>D<sub>3</sub> hydrochloride

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-12009S   |
| <b>CAS No.:</b>           | 1261398-44-0  |
| <b>Molecular Formula:</b> | C <sub>20</sub> <sup>13</sup> CH <sub>21</sub> D <sub>3</sub> ClN <sub>7</sub> O <sub>2</sub> S |
| <b>Molecular Weight:</b>  | 477.99  |
| <b>Target:</b>            | VEGFR; PDGFR; Autophagy; c-Fms; FGFR; c-Kit   |
| <b>Pathway:</b>           | Protein Tyrosine Kinase/RTK; Autophagy  |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis.       |



### BIOLOGICAL ACTIVITY

|                    |  |
|--------------------|--|
| <b>Description</b> | Pazopanib- <sup>13</sup> C, <sub>3</sub> D <sub>3</sub> (hydrochloride) is the deuterium and <sup>13</sup> C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].   |
| <b>In Vitro</b>    | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019 Feb;53(2):211-216.
- [2]. Harris PA, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. *J Med Chem.* 2008, 51(15), 4632-4640.
- [3]. Thakur A, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. *Microvasc Res.* 2011 Nov82(3):346-50.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA